Enrolling
Phase III
Chronic heart failure, once daily oral therapy
Assessing hospitalization rates and functional capacity over an 18 month follow up.
DCR 214, Cardiology
Inquire
Inquiries open for 2026 studies
Clinical research that treats people like people.
We design, manage, and report clinical trials across six therapeutic areas. Every study is held to ICH-GCP standards and independent IRB review, and every participant is looked after by someone whose name they know.
ICH-GCP compliant Operating since 1998 One site, in New York
28
years running clinical trials, and still answering our own phone
Independent IRB reviewEvery protocol is approved by an Institutional Review Board before enrollment opens.
ICH-GCP throughoutGood Clinical Practice governs monitoring, documentation, and reporting on every study.
Participant data protectedIdentifiable data is held under HIPAA compliant controls and never sold or shared for marketing.
Auditable by designSource data verification and a complete audit trail on every dataset we hand over.
0
Years conducting clinical research
0
Studies completed to protocol
0
Participants supported through trials
0
Therapeutic areas we work in
What we do
Full spectrum trial support, under one accountable team
Sponsors come to us for the parts of a trial that are easy to get wrong: the protocol, the regulatory file, the data, and the people.
Protocol design
Biostatisticians and medical writers turn a study question into an endpoint set and a protocol that survives review.
Regulatory affairs
Submission preparation, IRB liaison, and ongoing compliance across every jurisdiction a study touches.
Data management
Electronic data capture, validation, and query resolution that leaves a clean, analysis ready lock.
Recruitment and retention
Screening that fills enrollment targets without bending eligibility, and follow up that keeps participants in.
Therapeutic areas
Where our investigators do their deepest work
Six areas where our investigators have run the indication before, where the equipment is already in our building, and where we have referral relationships that make realistic recruitment possible.
Cardiology
Heart failure, hypertension, and lipid management studies, including device adjacent protocols.
Phase II to IVGastroenterology
Inflammatory bowel disease and functional GI disorders with endoscopy supported endpoints.
Phase II to IIINeurology
Migraine, epilepsy, and early neurodegenerative studies with standardized cognitive assessment.
Phase I to IIIRheumatology
Rheumatoid arthritis, psoriatic arthritis, and connective tissue disease programs.
Phase II to IVPulmonology
Asthma, COPD, and interstitial lung disease with onsite spirometry and imaging.
Phase II to IIIMetabolic and endocrine
Type 2 diabetes, obesity, and thyroid studies with long horizon retention planning.
Phase II to IV
Selected work
A sample of studies we have run
Study sponsors are named only with their permission. Where a sponsor is confidential, we describe the program in general terms.
Enrolling
Phase II
Moderate to severe Crohn's disease, biologic comparator
Endoscopic remission at week 52 as the primary endpoint, with every image scored by an independent central reviewer.
DCR 198, Gastroenterology
Inquire
Completed 2025
Phase III
Preventive migraine treatment, 12 month extension
Delivered on schedule with 94% retention through the extension period and a clean database lock.
DCR 176, Neurology
Read more
How we work
From first conversation to final report
1
Feasibility
We review the study question, the realistic recruitment pool, and the regulatory path before committing to a timeline.
2
Protocol and approvals
Protocol, statistical analysis plan, and IRB submission are prepared together so the file is internally consistent.
3
Conduct
The site is activated, participants are consented and enrolled, and monitoring runs continuously rather than in a panic at the end.
4
Lock and report
Queries are resolved, the database is locked, and you receive an analysis ready dataset with its full audit trail.
What a first visit looks like
Nobody joins a study without a screening visit first
Before anything else happens, you sit down with a clinician who checks whether the study is genuinely right for you. Basic measurements, a look at your history, and as many questions as you want to ask.
Thinking about taking part?
Talk to a person, not a form
We do not run online eligibility checks. Whether a study suits you depends on your medical history, your current medication, and a conversation with a clinician, none of which a web form can judge responsibly.
Email or call us and a member of the research team will talk you through what is currently open, what taking part would involve, and what it would ask of your time.
- There is no cost to take part in any study we run.
- Asking a question commits you to nothing at all.
- You may withdraw from a study at any point, without giving a reason and without affecting your normal care.
Investigators
The clinicians who lead our studies
Every study has a named principal investigator who is accountable for it from activation to close out.
Dr Ijaz Ahmed
Principal Investigator, Cardiology
Leads our heart failure and hypertension programs, with a particular focus on studies in older participants living with several conditions at once.
Cardiology, study lead since 2011
Dr Milagros Hernandes
Principal Investigator, Rheumatology
Runs our inflammatory arthritis portfolio and chairs the internal review that signs off every protocol before submission.
Rheumatology, study lead since 2014
Dr Intezam U. Khan
Principal Investigator, Neurology
Specializes in migraine and epilepsy trials, and built the standardized cognitive assessment protocol used in every neurology study we run.
Neurology, study lead since 2016
In their words
What sponsors and participants tell us
“They flagged a recruitment shortfall in month two rather than month nine, and came to the call with three options already costed. That is not the norm.”
“I was told exactly what each visit involved before I agreed to anything, and I was reminded more than once that I could stop. That is why I stayed in.”
“The database lock was the least stressful part of the program. Queries had been closed as we went, so there was nothing left hiding at the end.”
Have a study that needs running properly?
Tell us the indication, the endpoints, and the timeline you are working to. We will tell you honestly whether we are the right partner.